Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hexokinase–VDAC complex refers to the physical and functional association between hexokinase isoforms (especially hexokinase-I and hexokinase-II) and the voltage-dependent anion channel (VDAC) of the outer mitochondrial membrane. This interaction facilitates direct access of hexokinase to mitochondrial ATP, thereby supporting efficient glycolysis. Binding of hexokinase also confers protection against apoptosis by preventing the association of pro-apoptotic proteins (such as Bax) with the mitochondria and by modulating the mitochondrial permeability transition pore. The complex is particularly abundant in cancer cells due to upregulated hexokinase-II, promoting the metabolic phenotype known as the Warburg effect. Disruption of this protein–protein interaction sensitizes cells to cell death, making the hexokinase–VDAC complex an attractive, though challenging, therapeutic target for cancer and possibly other diseases involving mitochondrial dysfunction.
Inhibitors disrupt binding of hexokinase to VDAC, promoting apoptosis and sensitizing cells (notably cancer cells) to cell death
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hexokinase–VDAC complex.